Publications

Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis by Trias E et al. in Glia (2020).

Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice by Harrison JM et al. Neurobiol Dis (2020).

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial by Mora JS et al. in Amyotroph Lateral Scler Frontotemporal Degener (2019).

Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS by Trias E et al. in JCI Insight (2018).

Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALSby Trias E et al. in JCI Insight (2018).

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? by Petrov D et al. in Front Aging Neurosci (2017).

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis by Trias E et al. in J Neuroinflammation (2017).

Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient by Salvado M et al. in World J Gastroenterol (2016).

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study by Vermersch P et al. in BMC Neurol (2013).

Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer’s Disease by Li T et al. in J Alzheimers Dis (2020).

Masitinib for the treatment of mild to moderate Alzheimer’s disease by Folch J et al. in Expert Rev Neurother (2015).

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial by Piette F et al. in Alzheimers Res Ther (2011).

An evaluation of masitinib for treating systemic mastocytosis by Laforgia M et al. in Expert Opin Pharmacother (2019).

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study by Lortholary O et al. in Lancet (2017).

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor by Georgin-Lavialle S et al. in Eur J Haematol (2012).

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy by Moura DS et al. in PLoS One (2011).

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study by Paul C et al. in Am J Hematol (2011).

The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma by Lee-Fowler TM et al. in Int Arch Allergy Immunol (2012).

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics by Humbert M et al. in Allergy (2009).

Masitinib in treatment of pancreatic cancer by Waheed A et al. in Expert Opin Pharmacother (2018).

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer by Deplanque G et al. in Ann Oncol (2015).

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer by Mitry E et al. in Cancer Chemother Pharmacol (2010).

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model by Humbert M et al. in PLoS One (2010).

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro by Drayman N et al. in bioRxiv (2020).

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats by Belin-Rauscent A et al. in Psychopharmacology (2018).

The cKit Inhibitor, Masitinib, Prevents Diabetes-Induced Retinal Vascular Leakage by Kim SR et al. in Invest Ophthalmol Vis Sci (2016).

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report by Prosvicova J et al. in Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2016).

Local release of masitinib alters in vivo implantable continuous glucose sensor performance by Avula M et al. in Biosens Bioelectron (2015).

Neuroprotective effect of masitinib in rats with postischemic stroke by Kocic I et al. in Naunyn Schmiedebergs Arch Pharmacol (2015).

Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib by Avula MN et al. in Biomaterials (2014).

Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein by Zandvliet M et al. in J Vet Pharmacol Ther (2013).

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT by Dubreuil P et al. in PLoS One (2009).